March 3, 2020 / 12:33 PM / a month ago

BRIEF-Kura Oncology Receives Fast Track Designation For Tipifarnib In T-Cell Lymphomas

March 3 (Reuters) - Kura Oncology Inc:

* KURA ONCOLOGY RECEIVES FAST TRACK DESIGNATION FOR TIPIFARNIB IN T-CELL LYMPHOMAS

* KURA ONCOLOGY - PLANS TO INITIATE REGISTRATION-DIRECTED TRIAL OF TIPIFARNIB IN ADVANCED NODAL LYMPHOMAS OF TFH PHENOTYPE, INCLUDING AITL, IN H2 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below